MTD Group enhances global reach with acquisition of Ypsomed’s pen needles and blood glucose monitoring systems

Medical Technology and Devices (MTD) has announced the successful completion of its acquisition of Ypsomed’s Pen Needles and Blood Glucose Monitoring Systems (BGM) businesses. This strategic move, first revealed in March, represents a significant advancement in MTD’s mission to deliver superior solutions in diabetes and obesity care on a global scale.

Strategic Acquisition Bolsters Market Position

With the acquisition of Ypsomed’s businesses, MTD has solidified its position as the second-largest player in the global pen needles market. This deal not only enhances MTD’s leadership in diabetes care but also underscores its commitment to providing innovative solutions for both self-care and professional use. The integration of Ypsomed’s operations will increase MTD’s production capacity to over 2.5 billion pen needles annually.

Expanding Product Portfolio and Technological Advancements

The acquisition brings Ypsomed’s advanced technologies and trademarks into MTD’s portfolio, complementing its existing product range. MTD’s offerings now include the G34, noted for being the thinnest and shortest pen needle available. The expanded portfolio features a comprehensive range of pen needles with 3, 5, and 6 bevels, Click Technology for a secure fit, and single and dual protection safety options. MTD has also recently introduced Continuous Glucose Monitoring Systems (CGMs) in Italy and plans to launch new products including Blood Pressure Monitoring Systems (BPMs), nebulizers, footcare products, and insect repellents in 2024.

Entry into High-Growth Markets

The acquisition also provides MTD with an entry into high-growth markets such as China and India, significantly expanding its reach. Additionally, it strengthens MTD’s presence in established markets, including North America, Germany, and France. This strategic expansion is a critical step for MTD as it continues to enhance its global footprint and influence within the diabetes care industry.

Investment in State-of-the-Art Production Facilities

In line with its growth strategy, MTD is undertaking a substantial investment plan to develop cutting-edge production facilities for pen needles and lancets in Europe. These investments are designed to boost capacity, improve performance, and enhance the quality and ESG credentials of MTD’s production operations.

Expert Opinion on the Acquisition

Charles Bouaziz, CEO of MTD Group, described the acquisition as a transformative moment for the company. He emphasized that integrating Ypsomed’s pen needles and BGM businesses reinforces MTD’s position as a global leader in diabetes care and the second-largest producer of pen needles worldwide. Bouaziz highlighted that the strategic move will enable MTD to deliver innovative, high-quality solutions while expanding its market reach. He also noted the importance of the significant investments being made to scale operations efficiently and maintain high standards of quality.

MTD’s legal aspects of the acquisition were managed by Studio Legale LCA, with Roberto de Bonis, Sara Consoli, and Mario Niggeler leading the legal team.